Sorption of Interleukins 12 and 23 Using the Developed Magnetocontrollable Ustekinumab-Based Sorbent

The aim of the study was to assess the sorption capacity of Ustekinumab, a drug based on interleukins 12 (IL-12) and 23 (IL-23), when using it with a magnetocontrollable sorbent. MATERIALS AND METHODS. To reduce the concentration of proinflammatory cytokines (IL-12, IL-23), the blood of patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Gontar, I.P., Emelyanova, O.I., Rusanova, O.A., Zborovskaya, I.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Privolzhsky Research Medical University 2020
Materias:
Clinical Supplements
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596277/
https://www.ncbi.nlm.nih.gov/pubmed/34795995
http://dx.doi.org/10.17691/stm2020.12.4.09

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596277/
https://www.ncbi.nlm.nih.gov/pubmed/34795995
http://dx.doi.org/10.17691/stm2020.12.4.09

Ejemplares similares